Heshmatpour said he believes Israel and a future post-regime Iran could one day work together in the region.

Initial sales of that dural repair graft have started in the United States, giving the company its first foothold in the US market.

The company reported it has already simulated more than 350 trials with up to 90 percent accuracy.

The therapy inhibited up to 97% of pancreatic cancer cells and nearly 90% of colorectal cancer cells.